Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL)

Historical Holders from Q2 2021 to Q1 2025

Symbol
LYEL on Nasdaq
CUSIP
55083R104
Type / Class
Equity / Common Stock par value $0.0001 per share
Shares outstanding
279M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
150M
Holdings value
$95.9M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
100
Number of buys
50
Number of sells
-59
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARCH Venture Fund IX, L.P. 13.1% $19.7M 36.6M Robert Nelsen Dec 31, 2024
Foresite Capital Fund IV, L.P. 6.7% $10.5M 19.5M James Tananbaum Dec 31, 2024
BlackRock, Inc. 4.5% $7.14M 13.3M BlackRock, Inc. Dec 31, 2024

Institutional Holders of Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 979K $527K +$17.9K $0.54 6
2024 Q4 150M $95.9M +$14.6M $0.64 100
2024 Q3 128M $177M -$7.31M $1.38 115
2024 Q2 133M $194M -$1.42M $1.45 114
2024 Q1 133M $297M +$4.21M $2.23 124
2023 Q4 131M $255M +$952K $1.94 115
2023 Q3 122M $180M +$185K $1.47 100
2023 Q2 122M $389M +$15.2M $3.18 97
2023 Q1 117M $277M +$818K $2.36 95
2022 Q4 117M $405M +$13.8M $3.47 92
2022 Q3 112M $823M +$50.7M $7.33 86
2022 Q2 106M $688M +$42.2M $6.52 71
2022 Q1 99.5M $502M +$55.2M $5.05 75
2021 Q4 84.5M $654M -$25.7M $7.74 74
2021 Q3 82.5M $1.22B +$57.6M $14.80 61
2021 Q2 78.1M $1.27B +$1.27B $16.24 51